載入中
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
前收盤價
US$1.47
+US$0.02 · +1.38%
盤前
US$1.48
+US$0.01 · +0.68%
10月12日 上午4:00 ET
盤中時間採用ET。市場資料可能有所延遲。
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
日內區間
目前US$1.47
52週區間
目前US$1.47
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
17
估值過高
情緒
53
多空交錯
風險
66
高風險
動能
40
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
日內區間
目前US$1.47
52週區間
目前US$1.47
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7.21萬 USD | 7.21萬 USD | 7.21萬 USD | 7.21萬 USD | 7.13萬 USD |
| 銷貨成本 | 88.61萬 USD | 5838 USD | 5838 USD | 5838 USD | 5004 USD |
| 毛利 | −81.4萬 USD | 6.63萬 USD | 6.63萬 USD | 6.63萬 USD | 6.63萬 USD |
| 研究與開發 | 216.08萬 USD | 236.82萬 USD | 84.51萬 USD | 128.64萬 USD | 69.39萬 USD |
| 銷售、一般及管理費用 | 214.76萬 USD | 240.38萬 USD | 307.68萬 USD | 242.75萬 USD | 226.52萬 USD |
| 營業費用 | 346.67萬 USD | 477.2萬 USD | 392.19萬 USD | 369.39萬 USD | 281.06萬 USD |
| 利息收入 | 19.39萬 USD | 33.32萬 USD | 39.85萬 USD | 7.26萬 USD | 1210 USD |
| 利息支出 | 3.73萬 USD | 5084 USD | 4869 USD | 2199 USD | 3036 USD |
| 折舊和攤銷 | 1.14萬 USD | 6185 USD | — | — | — |
| 營業利益 | −428.07萬 USD | −470.57萬 USD | −385.56萬 USD | −362.77萬 USD | −274.43萬 USD |
| 淨利 | −422.77萬 USD | −439.29萬 USD | −370.07萬 USD | −390.86萬 USD | 390.37萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年6月3日 | 1:15 | — | — |
股票分割 | 2022年9月15日 | 1:50 | — | — |
已生效 2026年6月3日
1:15
已生效 2022年9月15日
1:50
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
